US generic drugmaker ANI Pharmaceuticals (Nasdaq: ANIP) today revealed that it has received approval from the US Food and Drug Administration of the Abbreviated New Drug Application for nilutamide tablets.
Trailing 12-month sales of Nilandron (nilutamide) were $23 million, according to IMS Health figures quoted by ANI, which also said it will immediately launch the product.
In 2013, French pharma major Sanofi (Euronext: SAN) sold Swiss specialty drug firm Covis Pharma full commercial rights to a batch of drug brands, including Nilandron.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze